Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gavai

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Bioorganic & Medicinal Chemistry Letters|June 30, 2010
Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonistsHai-Yun Xiao, Aaron Balog, Ricardo M Attar, et al.
ACS Medicinal Chemistry Letters|January 15, 2025
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate ApproachYam B Poudel, Julian C Lo, Derek J Norris, et al.
ACS Medicinal Chemistry Letters|February 14, 2024
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncologyLiqi He, Meng Yao Zhang, Matthew Cox, et al.
Journal of Medicinal Chemistry|October 14, 2009
Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinasesAshvinikumar V Gavai, Brian E Fink, David J Fairfax, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Gigabyte (Hong Kong, China)|March 4, 2024
Citizen science data on urban forageable plants: a case study in BrazilFilipi Miranda Soares, Luís Ferreira Pires, Maria Carolina Garcia, et al.
Gigascience|March 5, 2024
Leveraging citizen science for monitoring urban forageable plantsFilipi Miranda Soares, Luís Ferreira Pires, Maria Carolina Garcia, et al.
ACS Medicinal Chemistry Letters|July 21, 2022
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic PropertiesMatthew D Hill, Haiquan Fang, Derek Norris, et al.
Journal of Medicinal Chemistry|October 22, 2024
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) KinaseJennifer X Qiao, David Williams, Patrice Gill, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Bioorganic & Medicinal Chemistry Letters|June 30, 2010
Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonistsHai-Yun Xiao, Aaron Balog, Ricardo M Attar, et al.
ACS Medicinal Chemistry Letters|January 15, 2025
Structure-Based Design of Novel TLR7/8 Agonist Payloads Enabling an Immunomodulatory Conjugate ApproachYam B Poudel, Julian C Lo, Derek J Norris, et al.
ACS Medicinal Chemistry Letters|February 14, 2024
Identification and Optimization of Small Molecule Pyrazolopyrimidine TLR7 Agonists for Applications in Immuno-oncologyLiqi He, Meng Yao Zhang, Matthew Cox, et al.
Journal of Medicinal Chemistry|October 14, 2009
Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epidermal growth factor receptor 1 and 2 kinasesAshvinikumar V Gavai, Brian E Fink, David J Fairfax, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.
Bioorganic & Medicinal Chemistry Letters|April 11, 2015
BMS-871: a novel orally active pan-Notch inhibitor as an anticancer agentWeifang Shan, Aaron Balog, Claude Quesnelle, et al.
Gigabyte (Hong Kong, China)|March 4, 2024
Citizen science data on urban forageable plants: a case study in BrazilFilipi Miranda Soares, Luís Ferreira Pires, Maria Carolina Garcia, et al.
Gigascience|March 5, 2024
Leveraging citizen science for monitoring urban forageable plantsFilipi Miranda Soares, Luís Ferreira Pires, Maria Carolina Garcia, et al.
ACS Medicinal Chemistry Letters|July 21, 2022
Development of BET Inhibitors as Potential Treatments for Cancer: Optimization of Pharmacokinetic PropertiesMatthew D Hill, Haiquan Fang, Derek Norris, et al.
Journal of Medicinal Chemistry|October 22, 2024
Discovery and Synthesis of Heterobifunctional Degraders of Rearranged during Transfection (RET) KinaseJennifer X Qiao, David Williams, Patrice Gill, et al.
Pageof 8